In a phase 2 study combining dulanermin with FOLFOX6 and bevacizumab for colorectal cancer, high expression of GALNT14 evaluated by IHC has been found to significantly associate with PFS and OS in the treatment over the control arm, suggesting GALNT14 expression served as a predictor of sensitivity to cytotoxic agents [22]. Here, GALNT14 is linked to colorectal cancer.